Published in Mutat Res on June 25, 2010
APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci U S A (2002) 1.89
Preliminary analysis of azoxymethane induced colon tumors in inbred mice commonly used as transgenic/knockout progenitors. Int J Oncol (2003) 1.60
Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res (2008) 1.54
Planar spindle orientation and asymmetric cytokinesis in the mouse small intestine. J Histochem Cytochem (2007) 1.37
HDAC3 overexpression and colon cancer cell proliferation and differentiation. Mol Carcinog (2008) 1.29
Multifaceted roles of PGE2 in inflammation and cancer. Semin Immunopathol (2012) 1.29
Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression. Cancer Res (2006) 1.26
The p50-p50 NF-kappaB complex as a stimulus-specific repressor of gene activation. Mol Cell Biochem (2004) 1.23
Roles of cPLA2alpha and arachidonic acid in cancer. Biochim Biophys Acta (2006) 1.19
HDAC3 impacts multiple oncogenic pathways in colon cancer cells with effects on Wnt and vitamin D signaling. Cancer Biol Ther (2008) 1.13
Carcinogen-induced colon tumors in mice are chromosomally stable and are characterized by low-level microsatellite instability. Oncogene (2004) 1.08
mPGES-1 as a target for cancer suppression: A comprehensive invited review "Phospholipase A2 and lipid mediators". Biochimie (2010) 1.07
Deoxycholic acid promotes the growth of colonic aberrant crypt foci. Mol Carcinog (2007) 1.06
Genetic signatures of high- and low-risk aberrant crypt foci in a mouse model of sporadic colon cancer. Cancer Res (2004) 1.04
Anti-inflammatory effects of freeze-dried black raspberry powder in ulcerative colitis. Carcinogenesis (2010) 1.04
Selective PGE(2) suppression inhibits colon carcinogenesis and modifies local mucosal immunity. Cancer Prev Res (Phila) (2011) 1.03
Role of Notch signaling in colon homeostasis and carcinogenesis. Cancer Sci (2011) 1.02
Intestinal lineage commitment of embryonic stem cells. Differentiation (2010) 1.01
Ibuprofen inhibits activation of nuclear {beta}-catenin in human colon adenomas and induces the phosphorylation of GSK-3{beta}. Cancer Prev Res (Phila) (2011) 1.00
Microgenomics: Identification of new expression profiles via small and single-cell sample analyses. Cytometry A (2004) 0.99
Aberrant crypt foci in patients with a positive family history of sporadic colorectal cancer. Cancer Lett (2006) 0.98
Transgenic expression of cyclooxygenase-2 in mouse intestine epithelium is insufficient to initiate tumorigenesis but promotes tumor progression. Cancer Lett (2008) 0.97
Cytoplasmic phospholipase A2 deletion enhances colon tumorigenesis. Cancer Res (2005) 0.96
Inverse association between phospholipase A2 and COX-2 expression during mouse colon tumorigenesis. Carcinogenesis (2003) 0.95
Epidemiology of colonic aberrant crypt foci: review and analysis of existing studies. Cancer Lett (2006) 0.95
Aberrant crypt foci as predictors of colorectal neoplasia on repeat colonoscopy. Cancer Causes Control (2011) 0.93
CD13 is dispensable for normal hematopoiesis and myeloid cell functions in the mouse. J Leukoc Biol (2010) 0.93
Epigenetic alterations in RASSF1A in human aberrant crypt foci. Carcinogenesis (2006) 0.92
Expression of secretory phospholipase A2 in colon tumor cells potentiates tumor growth. Mol Carcinog (2007) 0.91
Suppression of colon carcinogenesis by targeting Notch signaling. Carcinogenesis (2013) 0.90
Cyclooxygenase-2 regulation in colon cancer cells: modulation of RNA polymerase II elongation by histone deacetylase inhibitors. J Biol Chem (2005) 0.90
Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells. Mol Carcinog (2011) 0.89
Microsatellite instability in aberrant crypt foci from patients without concurrent colon cancer. Carcinogenesis (2006) 0.89
The induction of aberrant crypt foci (ACF) in the colons of rats by trihalomethanes administered in the drinking water. Cancer Lett (2002) 0.89
Molecular alterations associated with sulindac-resistant colon tumors in ApcMin/+ mice. Cancer Prev Res (Phila) (2010) 0.88
Role of the alternating reading frame (P19)-p53 pathway in an in vivo murine colon tumor model. Cancer Res (2002) 0.87
Cytoplasmic phospholipase A2 levels correlate with apoptosis in human colon tumorigenesis. Clin Cancer Res (2005) 0.87
Dietary iron promotes azoxymethane-induced colon tumors in mice. Nutr Cancer (2004) 0.87
Suppression of kinesin expression disrupts adenomatous polyposis coli (APC) localization and affects beta-catenin turnover in young adult mouse colon (YAMC) epithelial cells. Exp Cell Res (2002) 0.85
Increased frequency of serrated aberrant crypt foci among smokers. Am J Gastroenterol (2010) 0.85
Nanoproteomic analysis of extracellular receptor kinase-1/2 post-translational activation in microdissected human hyperplastic colon lesions. Proteomics (2013) 0.84
Utilizing endoscopic technology to reveal real-time proteomic alterations in response to chemoprevention. Proteomics Clin Appl (2007) 0.84
Vitamin D resistance and colon cancer prevention. Carcinogenesis (2011) 0.83
The short chain fatty acid butyrate induces promoter demethylation and reactivation of RARbeta2 in colon cancer cells. Nutr Cancer (2008) 0.82
Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53. Biochem Pharmacol (2013) 0.82
Dietary methyl donor depletion protects against intestinal tumorigenesis in Apc(Min/+) mice. Cancer Prev Res (Phila) (2012) 0.82
cPLA2 is protective against COX inhibitor-induced intestinal damage. Toxicol Sci (2010) 0.81
Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors. Mol Carcinog (2003) 0.81
Number of aberrant crypt foci associated with adiposity and IGF1 bioavailability. Cancer Causes Control (2008) 0.80
Oxidative damage in colon and mammary tissue of the HFE-knockout mouse. Free Radic Biol Med (2003) 0.80
Azoxymethane-induced pre-adipocyte factor 1 (Pref-1) functions as a differentiation inhibitor in colonic epithelial cells. Carcinogenesis (2004) 0.80
Differential proteomics identifies PDIA3 as a novel chemoprevention target in human colon cancer cells. Mol Carcinog (2012) 0.80
Vascular endothelial growth factor and enhanced angiogenesis do not promote metastatic conversion of a newly established azoxymethane-induced colon cancer cell line. Mol Carcinog (2005) 0.79
p53 and its co-activator p300 are inversely regulated in the mouse colon in response to carcinogen. Toxicol Lett (2003) 0.79
Comment re: "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "Aberrant crypt foci in the adenoma prevention with celecoxib trial". Cancer Prev Res (Phila) (2008) 0.78
Circumvention and reactivation of the p53 oncogene checkpoint in mouse colon tumors. Biochem Pharmacol (2006) 0.78
The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci (2007) 0.78
Chlorogenic acid differentially alters hepatic and small intestinal thiol redox status without protecting against azoxymethane-induced colon carcinogenesis in mice. Nutr Cancer (2010) 0.78
Strain-specific homeostatic responses during early stages of Azoxymethane-induced colon tumorigenesis in mice. Int J Oncol (2007) 0.77
Murine models of ulcerative colitis. Arch Pharm Res (2003) 0.75
Multistage gene expression profiling in a differentially susceptible mouse colon cancer model. Cancer Lett (2003) 0.75